AF
IGMS

Amalgamated Financial’s IGM Biosciences IGMS Stock Holding History

Amalgamated Financial’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$36K Buy
+1,335
New +$24.9K ﹤0.01% 2557

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Amalgamated Financial's IGMS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in IGM Biosciences (IGMS) in Q1 2022: 1,335 shares worth $36K. The stake represents ﹤0.01% of the portfolio and ranks #2557 among its holdings.

93 funds tracked by Wall St. Rank hold IGMS as of Q1 2022.

  • Amalgamated Financial held 1,335 shares of IGM Biosciences worth $36K as of Q1 2022.
  • IGM Biosciences was a new Amalgamated Financial position in Q1 2022.
  • IGM Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2557 holding.
  • 93 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.